Apimeds Pharmaceuticals US, Inc.
AMEXAPUS cost to borrow surges 131% over one week to 13.93%, driven by short squeeze pressure in the micro-cap biotech name.
Snapshot as of 6 May 2026
No long-form analysis yet for APUS. Pulse alerts and the live data picture are available on ORTEX.
Open APUS on ORTEX →Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for APUS — free to start on ORTEX.
Sign up for free →Open APUS on ORTEX